Systemic Therapy of Metastatic Breast Cancer: The Truth Beyond the Clinical Trials

Publisher： Karger

E-ISSN： 1423-0232|76|4|247-253

ISSN： 0030-2414

Source： Oncology, Vol.76, Iss.4, 2009-02, pp. : 247-253

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prognosis for patients with metastatic breast cancer who achieve a no‐evidence‐of‐disease status after systemic or local therapy

By  

CANCER, Vol. 121, Iss. 24, 2015-12 ,pp. : 4324-4332

John Wiley & Sons Inc

Access to resources Recommend Favorite

What Can We Learn from Herceptin® Trials in Metastatic Breast Cancer?

By  

Oncology, Vol. 63, Iss. 1, 2002-11 ,pp. : 39-46

Karger

Access to resources Recommend Favorite

Adjuvant systemic therapy for elderly women with breast cancer

By Henry N Lynn   Diehl Kathleen M   Hayes Daniel F  

Women's Health, Vol. 2, Iss. 1, 2006-01 ,pp. : 75-87

Future Medicine

Access to resources Recommend Favorite

Editorial: Primary Systemic Therapy for Breast Cancer

By  

Reviews on Recent Clinical Trials, Vol. 12, Iss. 2, 2017-05 ,pp. : 66-66

Bentham Science Publishers

Access to resources Recommend Favorite

Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients

By  

THE PROSTATE, Vol. 78, Iss. 4, 2018-03 ,pp. : 250-256

John Wiley & Sons Inc

Access to resources Recommend Favorite